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Abstract 20 
The generation of effective levels of antigen-specific immunity at the mucosal sites of 21 
pathogen entry is a key goal for vaccinologists. We explored topical vaginal application as an 22 
approach to initiate local antigen-specific immunity, enhance previously existing systemic 23 
immunity or re-target responses to the mucosae. To deliver a protein vaccine formulation to 24 
the vaginal mucosal surface, we used a novel vaginal ring device comprising a silicone 25 
elastomer body into which three freeze-dried, rod-shaped, hydroxypropylmethylcellulose 26 
inserts were incorporated. Each rod contained recombinant HIV-1 CN54gp140 protein (167 27 
μg) +/- R848 (167 μg) adjuvant. The inserts were loaded into cavities within each ring such 28 
that only the ends of the inserts were initially exposed.  29 
Sheep received a prime-boost vaccination regime comprising intramuscular injection of 100 30 
μg CN54gp140 + 200 μg R848 followed by three successive ring applications of one week 31 
duration and separated by one month intervals. Other sheep received only the ring devices 32 
without intramuscular priming. Serum and vaginal mucosal fluids were sampled every two 33 
weeks and analysed by CN54gp140 ELISA and antigen-specific B cells were measured by 34 
flow cytometry at necropsy. Vaccine antigen-specific serum antibody responses were 35 
detected in both the intramuscularly-primed and vaginal mucosally-primed groups. Those 36 
animals that received only vaginal vaccinations had identical IgG but superior IgA responses. 37 
Analysis revealed that all animals exhibited mucosal antigen-specific IgG and IgA with the 38 
IgA responses 30-fold greater than systemic levels. Importantly, very high numbers of 39 
antigen-specific B cells were detected in local genital draining lymph nodes.  40 
We have elicited local genital antigen-specific immune responses after topical application of 41 
an adjuvanted antigen formulation within a novel vaginal ring vaccine release device. This 42 
regimen and delivery method elicited high levels of antigen-specific mucosal IgA and large 43 
numbers of local antigen-reactive B cells, both likely essential for effective mucosal 44 
protection. 45 
Introduction 46 
While it is relatively easy to elicit antigen-specific serum antibodies, it is much more difficult 47 
to establish meaningful levels of specific antibodies at mucosal surfaces, the major route of 48 
viral invasion. In this study, we sought to determine if mucosal vaccination using topical 49 
vaginal application could initiate local antigen-specific immunity, and/or enhance or re-target 50 
previously existing systemic immunity to the mucosae. Previous studies in mice have shown 51 
that vaccines generating high levels of systemic antigen-specific immunity can lead to the 52 
appearance of genital tract mucosal surface responses, derived from the systemic 53 
compartment [1-3]. Also in mice, studies have shown that direct mucosal vaccination via the 54 
intranasal, sublingual or intravaginal routes can efficiently enhance immune responses at 55 
other mucosal surfaces. This observation is generally attributed to common mucosal linkage, 56 
but this distribution of mucosal associated responses has been found to be very weak or 57 
absent in larger animals, and particularly man [4-7]. In an effort to generate local mucosal 58 
immunity, a number of researchers have explored genital tract targeted vaccination to 59 
establish regional vaccine specific immunity by injecting genital tract associated lymph nodes 60 
or inoculating the vagina mucosae topically. Compared with parenteral immunisations, these 61 
mucosal-directed interventions elicited higher levels of both B and T cell vaccine specific 62 
immune responses [8, 9]. 63 
Polymeric intravaginal rings have a long history of use in providing controlled release of 64 
small-molecule therapeutics for hormonal contraception, hormone replacement therapy, HIV 65 
prevention and other clinical indications within women’s healthcare [10-13]. The application 66 
of vaginal ring technology to controlled release of macromolecules, including protein 67 
antigens, is considerably more challenging owing to the thermal instability of proteins under 68 
the processing conditions commonly used to manufacture rings and the limited permeability 69 
of proteins in the polymeric materials. Nonetheless, a small number of papers have been 70 
published reporting ring technologies offering sustained/controlled release of macromolecular 71 
therapeutic agents [14-16]. We previously reported a silicone elastomer vaginal ring device 72 
comprising a one-piece ring body into which various drug-loaded inserts could be placed 73 
[15]. The body of this ring device had a similar design to that of the matrix-type dapivirine-74 
releasing vaginal ring being developed for HIV prevention by the International Partnership 75 
for Microbicides [17-19], except for the inclusion of three small cavities for placement of the 76 
protein drug delivery inserts. With this ring design, it is possible to deliver combinations of 77 
macromolecular and small molecule therapeutic agents (e.g. HIV antigen + HIV microbicide 78 
combinations) at independently-controlled release rates. In this study, we sought to establish 79 
whether this vaginal ring device could be used to deliver recombinant HIV-1 envelope 80 
protein CN54gp140 as a vaccine cargo that could be ‘seen’ by the immune monitoring system 81 
of the female sheep genital tract. The sheep vagina and cervix are anatomically and 82 
histologically similar and of comparative dimensions to the human female genital tract and 83 
have been used to test the delivery and pharmacokinetics of a variety of anti-HIV retrovirals 84 
and contraceptives within vaginal ring devices [20-22]. We also examined the role of an 85 
adjuvant in eliciting immune responses, its effect on the vaginal vault and detailed the 86 
relative antigen-specific humoral immune responses in the mucosal and systemic 87 
compartments.  88 
Results 89 
 90 
Vaccine Carrier System: Release of Vaccine Antigen  91 
We first assessed the release kinetics of the CN54gp140 vaccine antigen from covered rod-92 
type devices comprising a hydroxypropyl methylcellulose (HPMC) + CN54gp140 ± R848 93 
freeze-dried insert contained within a silicone elastomer tube. The recombinant HIV 94 
Envelope (Env) protein was released into 2 mL of either PBS (pH 7.2) or a simulated vaginal 95 
fluid (SVF; pH 4.2) to model release within the vaginal vault. CN54gp140 protein released 96 
into the media was quantified using a specific capture ELISA with a known concentration 97 
CN54gp140 standard curve. 98 
 99 
Figure 1: CN54gp140 in vitro release profile. Individual freeze-dried silicone elastomer 100 
rods were laced into 2 mL release media (PBS, pH 7.2 or SVF, pH 4.2). Rods contained 101 
CN54gp140 alone (167 µg) or CN54gp140 + R848 (167 µg each). The amount of 102 
CN54gp140 released into the 2 mL media was measured by quantitative ELISA and plotted 103 
as cumulative % release. Plot symbols represent the mean ± standard deviation of six 104 
replicates.  105 
The CN54gp140 protein was released in a sustained manner over a period of 24 h, with >99 106 
% of the total protein being released by all rod formulations in either PBS or SVF at the 24 h 107 
sample timepoint (Fig. 1). However, there were clear differences in the release kinetic 108 
depending on the nature of the release medium and whether the formulation contained R848. 109 
Freeze-dried rods released the protein more quickly into the low pH SVF media than PBS 110 
and rods containing R848 were more easily reconstituted in solution. When incubated in 111 
SVF, CN54gp140 + R848 rods released 88% of the recombinant protein within 6 h and 98% 112 
in 12 h whereas in PBS pH 7.2 67% release is achieved in 6 h and 84% in 12 h. Freeze-dried 113 
CN54gp140 alone released 71% (6 h) and 86% (12 h) of the recombinant protein when 114 
incubated in SVF, and 53% (6 h) and 70% (12 h) when incubated in PBS pH 7.2 (Fig. 1). 115 
 116 
Mixed route prime-boost combinations with TLR7/8 adjuvantation elicit high levels of 117 
CN54gp140-specific humoral immunity. 118 
We initiated a series of vaccinations to assess the ability of silicone elastomer intravaginal 119 
ring devices to deliver recombinant antigen directly to the cervicovaginal mucosa and elicit 120 
systemic or local vaccine antigen-specific humoral immunity. Sheep received either an 121 
intramuscular (IM) priming vaccination of 100 µg CN54gp140 + 200 µg R848 adjuvant 122 
followed by three intravaginal ring immunisations at monthly intervals, or intravaginal rings 123 
without any prior IM priming vaccination. The intravaginal rings all contained 500 µg 124 
recombinant CN54gp140 antigen, matched to previous intravaginal doses used in humans 125 
[23] . Two of the four animal groups received intravaginal rings that also contained the 126 
TLR7/8 adjuvant R848 (groups 1 and 2) while the other two groups received rings containing 127 
CN54gp140 antigen without any R848 adjuvantation (groups 3 and 4; Table 1). A final 128 
control group of sheep received four IM immunisations at monthly intervals (group 5; Table 129 
1). The sheep were bled every two weeks and vaginal samples were taken at regular intervals, 130 
according to the immunisation and sampling schedule as shown (Fig. 2). 131 
 132 
Table 1: Sheep groups and immunization schedule (n = 5). IM – intramuscular 133 
administration of 100 µg CN54gp140 + 200 µg R848; IVag – intravaginal administration of 134 
500 µg CN54gp140 ± 500 µg R848. 135 
Group 
Day of Immunization  
0 28 56 84 
1 IM IVag / gp140 + R848 IVag / gp140 + R848 IVag / gp140 + R848 
2 None IVag / gp140 + R848 IVag / gp140 + R848 IVag / gp140 + R848 
3 IM IVag / gp140 only IVag / gp140 only IVag / gp140 only 
4 None IVag / gp140 only IVag / gp140 only IVag / gp140 only 
5 IM IM IM IM 
 136 
 137 
Figure 2: Vaccination, bleed and vaginal sampling schedule. Two-year-old sheep were 138 
immunised at monthly intervals using intravaginal rings containing CN54gp140 HIV Env 139 
antigen +/- R848 adjuvant. The rings were maintained in place at the cervicovaginal area for 140 
1 week before removal. Some sheep received a prior IM vaccination one month before the 141 
insertion of the rings. Animals were bled weekly and had vaginal mucosal antibody Weck-142 
Cel® swabs taken at the times indicated. 143 
 144 
 Sheep that received an IM prime with adjuvant and were then boosted with an 145 
intravaginal ring device containing adjuvanted antigen exhibited strong generation of 146 
systemic antigen-specific humoral responses to the HIV Env CN54gp140 vaccine protein, 147 
increasing mean blood serum antigen-specific IgG antibody levels from 6.35 µg/mL (day 28 148 
after IM prime) to 1375 µg/mL (day 42, two weeks after the IVag ring boost), a 216-fold 149 
increase (Fig. 3a, Table 2). Indeed, the gp140-Specific IgG responses initially elicited by the 150 
R848 adjuvanted IM injection were enhanced after each successive ring application reaching 151 
peaks of 2228 µg/mL at day 70, two weeks after the second ring application, and 2683 µg/mL 152 
at day 98, two weeks after the third and final ring was inserted. In animals that did not receive 153 
any IM prime (group 2 in Table 1) the first ring application was able to generate antigen-154 
specific humoral immunity that was detectable in the serum. Interestingly, the second ring 155 
application substantially boosted the serum IgG gp140-specific responses by 70-fold, from 156 
10.7 µg/mL to 739 µg/mL at the peak response two weeks after insertion of the IVag rings 157 
and the third ring application in these IM unprimed animals further boosted the serum 158 
antigen-specific IgG response to 3070 µg/mL at two-weeks post application, levels 159 
equivalent to those measured in the group 1 IM primed animals (Fig. 3a, Table 2). A 160 
comparison of the antigen-specific IgG antibody levels between the IM primed (group 1) and 161 
unprimed (group 2) animals revealed that the peak levels on day 28 and day 42 were 162 
statistically different (**p = 0.0079) with there being no difference at any other time. 163 
 164 
Figure 3: CN54gp140 antigen-specific antibody serum responses to 500 μg vaccine 165 
antigen in the presence of 500 μg R848 adjuvant per vaginal ring. IM Primed – animals 166 
received an IM prime at day 0 then three vaginal ring placements, each retained in situ for 7 167 
days, at monthly intervals. Unprimed – animals received the vaginal rings without a prior IM 168 
vaccination. The shaded areas indicate the 7-day periods during which a ring device was 169 
present in the sheep vagina. (A) Vaccine antigen-specific IgG and (B) IgA responses. Data 170 
compared with a Mann-Whitney test (n = 5 per group). 171 
 172 
The systemic antigen-specific IgA achieved significantly higher levels in animals that did not 173 
have any IM priming immunisation in comparison to those animals that had the potent 174 
systemic prime (Fig. 3b, Table 2).  At the end of the vaccination schedule, following three 175 
separate intravaginal ring inoculations, the antigen-specific IgA present in the serum 176 
compartment was significantly higher than in those animals that had received an IM prime 177 
(*p = 0.0317), although levels were greater than 3 logs lower than that seen for specific IgG. 178 
We next examined the antigen-specific immunity at the mucosal surface. We sampled the 179 
vaginal mucosae at various times during the schedule and measured gp140-specific IgG and 180 
IgA (Fig. 4). IM primed gp140-specific mucosal IgG responses were effectively enhanced by 181 
intravaginal vaccination with the ring device that contained antigen adjuvanted with R848 182 
and antibody levels were boosted by subsequent ring applications. The specific antibody 183 
levels were statistically different between the IM primed and the unprimed groups at day 42, 184 
2 weeks after and at day 56, one month after the insertion of the first ring (Fig. 4a; **p = 185 
0.0079). There were no statistical differences at other sampling timepoints, and at the end of 186 
the vaccination schedule (after three intravaginal ring inoculations) the CN54gp140 antigen-187 
specific antibody levels were equivalent (Fig. 4a, Table 2). Interestingly, antigen-specific 188 
mucosal IgA followed the same pattern. Levels were statistically different after the first ring 189 
application (day 56), where the IM primed group had higher levels in the vaginal vault, but 190 
after the second and then the final ring vaccination the levels were equivalent. Importantly, 191 
the levels of mucosal IgA were substantially higher at the mucosal surface compared to the 192 
systemic serum compartment. Animals that had not been previously primed with an IM 193 
vaccination had 20-fold higher IgA in the vaginal vault while those that had received an IM 194 
prime followed by immunisation with the vaginal rings exhibited a marked difference, with 195 
the vaginal vault having 400-fold more specific antibody when compared to the serum 196 
responses (Figs. 3b, 4b and Table 2).  197 
 198 
Figure 4: CN54gp140 antigen-specific antibody mucosal responses to 500 μg vaccine 199 
antigen in the presence of 500 μg R848 adjuvant per vaginal ring. IM Primed – animals 200 
received an IM prime at day 0 then three vaginal ring placements, each retained in situ for 7 201 
days, at monthly intervals. Unprimed – animals received the vaginal rings without a prior IM 202 
vaccination. The shaded areas indicate the 7-day period during which a ring device was 203 
present in the sheep vagina. (A) Vaccine antigen-specific mucosal IgG and (B) mucosal IgA 204 
responses. Data compared with a Mann-Whitney test (n = 5 per group). 205 
 206 
 207 
 208 
Table 2: Serum and mucosal IgG and IgA levels (μg/mL) 2 weeks after each vaginal ring 209 
insertion (Days 42, 70 and 98) and at end of vaccination schedule (Day 112) (+/- SD in 210 
parentheses). IM – intramuscular administration of 100 µg CN54gp140 + 200 µg R848; IVag 211 
– intravaginal administration of 500 µg CN54gp140 ± 500 µg R848. A dash within a cell 212 
indicates that antibody levels were not detected (n = 5 per group). 213 
Sheep 
group 
Immunization 
schedule* 
Antibody 
response 
Sample Day 
42 70 98 112 
1 
IM + 3x IVag 
(gp140+R848) 
IgG systemic 
IgG mucosal 
IgA systemic 
IgA mucosal 
1375.9 (482.6) 
68.3 (40.2) 
0.071 (0.024) 
0.286 (0.097) 
2228.5 (804.8) 
108.6 (53.1) 
0.157 (0.05) 
14.6 (4.8) 
2682.7 (488.2) 
156.1 (67.0) 
0.163 (0.061) 
18.5 (11.9) 
1103.9 (112.6) 
49.1 (14.1) 
0.063 (0.029) 
25.13 (20.9) 
2 
3x IVag only 
(gp140+R848) 
IgG systemic 
IgG mucosal 
IgA systemic 
IgA mucosal 
10.65 (7.76) 
0.37 (0.34) 
0.005 (0.005) 
– (–) 
738.4 (279.5) 
27.9 (8.6) 
0.486 (0.167) 
4.64 (3.7) 
3069.6 (706.2) 
88.45 (43.2) 
0.891 (0.264) 
17.35 (13.19) 
1543.4 (464.9) 
50.9 (19.3) 
0.666 (0.234) 
13.32 (6.93) 
3 
IM + 3x IVag 
(gp140 only) 
IgG systemic 
IgG mucosal 
IgA systemic 
IgA mucosal 
1.08 (0.43) 
– 
– 
– 
8.63 (5.3) 
– 
– 
– 
7.57 (3.8) 
– 
– 
– 
4.38 (2.0) 
– 
– 
– 
4 
3x IVag only 
(gp140 only) 
IgG systemic 
IgG mucosal 
IgA systemic 
IgA mucosal 
0.382 (0.22) 
– 
– 
– 
0.255 (0.05) 
– 
– 
– 
0.35 (0.09) 
– 
– 
– 
0.726 (0.53) 
– 
– 
– 
5 
IM only 
(gp140+R848) 
IgG systemic 
IgG mucosal 
IgA systemic 
IgA mucosal 
735.0 (269.9) 
3.183 (1.09) 
– 
– 
1971.6 (568.2) 
8.489 (3.07) 
– 
– 
1272.1 (425.3) 
5.992 (2.16) 
– 
– 
680.1 (189.2) 
4.465 (1.3) 
– 
– 
 214 
Sheep immunised with intravaginal rings without local mucosal R848 adjuvantation fail to 215 
elicit significant CN54gp140-specific humoral immunity. 216 
In order to determine the contribution of the R848 TLR7/8 adjuvant to the size and kinetics of 217 
the immune response, we next examined the elicitation of antigen-specific serum and 218 
mucosal IgG and IgA in animals that were immunised with intravaginal rings that contained 219 
antigen but no R848 adjuvant. Sheep received an R848 adjuvanted IM prime and were then 220 
boosted with a vaginal ring device containing only gp140 antigen. The systemic CN54gp140-221 
specific IgG levels were very low, though the response was enhanced after the second ring 222 
application but not after third. Animals that had not received an IM priming vaccination had 223 
statistically higher levels of mucosal IgG than primed animals at day 70 (p = 0.0159; two 224 
weeks after the 2nd ring insertion), day 84 (p = 0.0075; four weeks after the second ring 225 
insertion) and at day 98 (p = 0.0317; two weeks after the third ring insertion. However, peak 226 
systemic responses in these animals that did not receive the R848 adjuvant with the 227 
CN54gp140 vaccine in the ring were 300-fold lower than those seen when using rings 228 
containing R848 (Fig 3a). In these animals no antigen-specific IgA was detected throughout 229 
the vaccination schedule (Fig. 5a, b and Table 2). 230 
 231 
 232 
Figure 5: CN54gp140 antigen-specific antibody serum responses to 500 μg vaccine 233 
antigen in the absence of R848 adjuvantation. IM primed – animals received an IM prime 234 
at day 0 then three vaginal ring placements, each retained in situ for 7 days, at monthly 235 
intervals. Unprimed – animals received the vaginal rings without a prior IM vaccination. The 236 
shaded areas indicate the 7-day periods when the vaginal ring was present. (A) Vaccine 237 
antigen-specific IgG and (B) IgA responses. Data compared with a Mann-Whitney test (n = 5 238 
per group). 239 
 240 
 241 
Animals that did not receive an IM prime mounted only barely detectable antigen-specific 242 
IgG responses that were 2000-fold lower than animals that also received no IM prime but 243 
were exposed to R848 adjuvanted protein within the intravaginal rings (Figs. 3 and 5). There 244 
were no detectable antigen-specific IgG or IgA mucosal antibody responses in any of the 245 
animals that were vaccinated with intravaginal rings containing antigen without R848 246 
adjuvant. At necropsy, there were no antigen-reactive cells in any of the compartments tested 247 
(Table 2). 248 
 249 
As a comparison, animals that received four IM vaccinations at monthly intervals with R848 250 
adjuvanted CN54gp140 protein produced a good systemic IgG response reaching a maximum 251 
peak two weeks after the third vaccination with a mean of 1972 μg of CN54gp140 antigen-252 
specific IgG (Fig. 6). The subsequent fourth vaccination failed to augment this peak response 253 
further. There was no systemic or mucosal antigen-specific IgA detected in these animals 254 
during the entire vaccination schedule (Fig. 6). Interestingly, systemic responses (IgG and 255 
IgA) were lower than those seen in animals receiving mucosal adjuvanted rings (Table 2).  256 
 257 
Figure 6: CN54gp140 antigen-specific serum antibody responses in animals that 258 
received only IM vaccinations. Animals received an IM prime of 100 μg vaccine antigen 259 
plus 200 μg R848 adjuvant at day 0 then three IM boost vaccinations with the same vaccine 260 
composition at monthly intervals. Vaccine antigen-specific IgG and IgA responses (n = 5 per 261 
group). 262 
 263 
Mucosal antigen-specific IgG was detected at low levels in the vaginal mucosal samples and 264 
followed the profile of the systemic serum IgG precisely indicating the antibody present was 265 
derived from serum exudate (Fig. 7). Again, there was no detectable antigen-specific IgA in 266 
the vaginal samples taken throughout the vaccination regimen (Fig. 7). 267 
 268 
Figure 7: CN54gp140 antigen-specific vaginal antibody responses in animals that 269 
received only IM vaccinations. Animals received an IM prime of 100 μg vaccine antigen 270 
plus 200 μg R848 adjuvant at day 0 then three IM boost vaccinations with the same vaccine 271 
composition at monthly intervals. Vaccine antigen-specific mucosal IgG and mucosal IgA 272 
responses (n = 5 per group). 273 
 274 
 275 
Sheep that received intravaginal rings containing both CN54gp140 and R848 276 
adjuvantation contained large numbers of antigen-binding cells in the local vaginal 277 
draining LN 278 
The notable observation that the vaginal vault contained dramatically higher levels of 279 
antigen-specific antibody in either unprimed or IM primed animals that received intravaginal 280 
rings containing CN54gp140 + R848 led us to hypothesise that this local production may be 281 
reflective of local B cell expansion and residency in the lymph nodes draining the female 282 
genital tract. At the end of the immunogenicity study, we inserted a new ring (500 μg 283 
CN54gp140 + 500 μg R848) into each sheep at day 112 before the animals were necropsied 284 
one week later. Our aim was to determine the inflammation caused by the ring after a typical 285 
7-day application and also to examine the local lymph nodes immune response at the same 286 
time as responses in the systemic compartments. At necropsy, we removed the external iliac 287 
lymph nodes, spleen and peripheral blood from each sheep, processed to isolate lymphocytes 288 
and then incubated with a fluorochrome-labeled vaccine antigen CN54gp140-Alexa 647 or a 289 
control Tetanus Toxoid antigen (TT)-Alexa 647. B lymphocytes expressing an antigen 290 
receptor on their surface should bind the labeled antigen and the number and intensity of the 291 
bound labeled antigen positive cells was determined using flow cytometry. While the 292 
peripheral blood cells showed very low antigen-specific staining and the splenocytes 293 
demonstrated slightly more, the level of specific staining in the draining lymph nodes clearly 294 
revealed a sizeable population of cells with cell surface receptors that specifically bound the 295 
vaccine CN54gp140 antigen in comparison to the control (Fig. 8). In the absence of R848 the 296 
vaginal ring containing the unadjuvanted CN54gp140 protein did not elicit this population of 297 
antigen binding cells in the vaginal draining LN (Supplementary Material S1). 298 
 299 
Figure 8: Elicitation of Antigen-Specific B cells in vaginal local draining lymph nodes. 300 
Cells were harvested from the peripheral blood, the spleen or the vaginal external iliac lymph 301 
nodes and stained with Alexa-647 conjugated recombinant CN54gp140 protein. 302 
 303 
Nine out of the 10 animals that received intravaginal rings containing antigen and R848 304 
adjuvant had large populations of antigen-specific cells in the draining external iliac lymph 305 
nodes (Table 3). We statistically compared the levels of antigen-stained cells between the 306 
blood, spleen and the vaginal draining lymph node using an unpaired t tests with Welch’s 307 
correction for unequal variances and found that as expected there was no difference between 308 
the levels of specific cells found in the blood and spleen for both groups of animals. 309 
However, group 1 iliac LN contained statistically higher numbers of specific cells than both 310 
the blood (p = 0.0207) and the spleen (p = 0.0225), and group 2 iliac LN also had higher 311 
numbers though only just achieving statistical differences to the blood and the spleen (p = 312 
0.0499). 313 
 314 
Table 3: Mean percentage of background control subtracted antigen-specific cells in each 315 
tissue (n=5 per group) (+/- SD in parentheses). 316 
Sheep group 
Mean % CN54gp140 specific cells 
Blood Spleen Iliac LN 
1 0.05 (0.012) 0.16 (0.078) 2.45 (0.802) 
2 0.04 (0.014) 0.08 (0.028) 2.28 (0.839) 
3 – – – 
4 – – – 
 317 
An important consideration when using intravaginal rings that release antigen and an 318 
adjuvant at the mucosal surface is the degree of associated inflammation. Each ring that was 319 
removed was examined for the presence of blood and none was found. At necropsy, each 320 
vagina was removed and closely examined for redness, tissue pathology and inflammation. 321 
The vaginal wall appeared normal with no apparent inflammation; a photograph showing a 322 
typical vagina with the ring still in situ is shown (Supplementary material S2).  323 
 324 
325 
Discussion 326 
 327 
Conventional vaginal ring devices fabricated from hydrophobic polymers provide controlled 328 
release of low molecular actives via a molecular permeation mechanism. This involves 329 
dissolution of the drug in the surrounding polymer, diffusion of the dissolved drug molecule 330 
to the ring surface, and then partitioning into the vaginal fluid. This simple permeation 331 
mechanism is generally not useful for release of biomolecules, since their hydrophilic 332 
character and high molecular weight result in poor solubility and diffusion through the 333 
polymeric material. In the past ten years, the application of ring technology to vaginal 334 
administration of HIV microbicide molecules has led to very considerable innovation in 335 
vaginal ring design, mostly aimed at providing viable formulation solutions for lead 336 
candidate microbicides having a very broad range of physicochemical properties [10]. 337 
However, despite these advances, the development of practical ring devices that are simple 338 
and inexpensive to manufacture and can offer clinically significant drug release rates remains 339 
a challenge [16]. Here, we opted to use a ring technology previously reported for the 340 
sustained release of a model protein and a monoclonal antibody [15]. This approach 341 
permitted the silicone elastomer ring body and the antigen-loaded freeze-dried rod inserts to 342 
be manufactured separately, thereby reducing exposure of the antigen to the high processing 343 
temperatures normally associated with ring manufacture and exploiting use of established 344 
lyophilization techniques for formulation of the antigen. With this ring design, it is also 345 
possible to easily vary the dose of the antigen by reducing or increasing the number of 346 
inserts, or to incorporate an antiretroviral microbicide, such as dapivirine, into the ring body 347 
to produce a combination microbicide-vaccine formulation.  348 
This current study examined the potential of the vaginal mucosae as a site of initiation and/or 349 
enhancement of vaccine antigen-specific immune responses. We compared a direct 350 
vaccination to a boost of an existing IM-elicited immune response using the vaginal ring 351 
delivery device, with the expectation that direct delivery of antigen to the vaginal mucosae 352 
alone might not have the potency to initiate a combined systemic and vaginal antigen-specific 353 
immune response. Surprisingly, we discovered that vaginal vaccination alone was as potent 354 
(group 2) as IM-prime, vaginal boost (group 1, Table 2), with R848 being necessary to 355 
induce high levels of antigen-specific systemic and mucosal antibody responses. Importantly 356 
vaginal vaccination with R848 was essential to induce localised mucosal responses. Further 357 
studies are now required to address the issue of dose response in relation to optimization of 358 
antigen:adjuvant ratios. Animals receiving only IM immunisation (group 5) expressed no 359 
antigen specific vaginal IgA while IgG levels were 1/10th of those seen in groups 1 and 2 360 
(Table 2). These data are supported by the local expansion of specific B cells in lymph nodes 361 
draining the genital tract. In the absence of defined B cell markers for sheep, the nature and 362 
phenotype of local responding B and T cell responses will require further study in non-human 363 
primate and/or clinical studies. 364 
The lack of immune response to non-adjuvanted vaginal vaccination alone and very 365 
limited response following an intramuscular prime (groups 3 and 4, Table 2) reflects human 366 
clinical studies [24, 25].  Very few clinical studies have assessed response to adjuvanted 367 
vaginal vaccination. In a previous human study using CN54gp140 and HSP70 as an adjuvant, 368 
IVag administration failed to induce detectable systemic or mucosal antibody responses but 369 
did induce adaptive CD4 and CD8 T-cell proliferative responses [9]. The difference in 370 
response may reflect difference in the adjuvant potential of HSP70 and R848, the latter 371 
associated with promoting mucosal IgA [6]. Indeed, two additional clinical studies of vaginal 372 
immunisation performed using recombinant cholera toxin subunit B (CTB), were shown to 373 
elicit vaginal and systemic antibodies [23, 26, 27]. This may reflect the “self-adjuvanting” 374 
properties of CTB, known to be an effective mucosal adjuvant for other proteins [28]. None 375 
of these studies assessed responses to vaccine delivered by vaginal rings that may offer 376 
additional advantage through direct localized delivery over topical administration of an 377 
aqueous formulation. 378 
Both our data and previous observations in humans suggest that the inclusion of a 379 
mucosal adjuvant is likely necessary to establish effective and long-lasting mucosal immune 380 
responses. However, the downsides of using an inflammatory mediator in genital mucosal 381 
tissue are clear – the recruitment and activation of CD4 T cells has the potential to increase 382 
mucosal targets for HIV-1. Also, inflammation may compromise the integrity of the mucosal 383 
barrier increasing risk of infection not only by HIV but also other sexually transmitted 384 
infections (STIs), although an increase in mucosal expression of interferons by adjuvants may 385 
protect against pathogen infection [29, 30]. Nevertheless, this potential inflammation is likely 386 
to be short-lived. In this respect, the fact that no localised signs of inflammation were visually 387 
apparent at the end of the study is encouraging. A major advantage of the ring device is that a 388 
topical antiretroviral, such as the lead candidate microbicide dapivirine, can readily be co-389 
delivered to the precise site of any local inflammation, protecting the mucosae during the 390 
vaccination window. In addition, the adjuvant quantity or adjuvant combinations can be 391 
tailored to maximise the immune response while preventing unnecessary bystander 392 
inflammation [2, 31, 32]. 393 
In summary, the ability to generate these vaccine-reactive B cells with local 394 
cervicovaginal adjuvanted vaccine administration using a ring release delivery system is a 395 
significant and important observation, with potential application to the future delivery 396 
modalities for any vaccine against pathogens that enter through genitourinary mucosae.  397 
 398 
Conclusions 399 
In this present study we have explored an intravaginal ring device for administration of a 400 
vaccine antigen at a cervicovaginal mucosal surface. We demonstrated that in the presence of 401 
a potent adjuvant a local mucosal antibody response can be generated with high levels of 402 
vaccine antigen-specific antibody and also that a population of vaccine antigen-reactive cells 403 
are established within the local draining lymph nodes, ready to respond to any re-infection 404 
with the same or similar pathogen. In this study, we used HIV Env gp140 as a model antigen 405 
but our findings are likely to be applicable to any mucosal vaccine candidate and relevant to a 406 
number of sexually transmitted diseases. 407 
  408 
Materials and Methods 409 
 410 
Ethics Statement 411 
The animal studies were approved by the Ethical Review Board of St. George’s, University 412 
of London where the experiments were carried out and work was performed in strict 413 
compliance with project and personal animal experimentation licences granted by the UK 414 
government in accordance with the Animals in Scientific Procedures Act (1986). Animals 415 
received minimal handling and their physical condition was monitored at least twice daily. 416 
All procedures were performed under isoflurane anaesthesia when appropriate, and all efforts 417 
were made to minimize suffering. There was a detailed protocol in place, as per requirement 418 
of the humane endpoints described in the animal licence, for early euthanasia in the event of 419 
onset of illness or significant deterioration in condition. For sheep the humane endpoints 420 
included; loss of appetite sufficient to lead to weight loss - the animals were monitored for 421 
weight weekly, loss of movement, sedentary state, calls of distress indicating pain or 422 
discomfort, bruising at site of blood withdrawal, excessive or uncontrolled bleeding from site 423 
of blood withdrawal, incontinence, breathing difficulty, infection or necrosis at site of 424 
sampling (leg vein and vaginal). The presence of one of these indicators led to an assessment 425 
by a veterinary surgeon and further welfare of the animals was directed by them. In the case 426 
of an emergency if an animal became seriously ill or injured at any point when they were on 427 
the designated premises then the animal would be first stunned by captive bolt and then killed 428 
by exsanguination before the animal regained consciousness (a non-schedule 1 method). If it 429 
were possible to handle the animal without causing it further stress and/or injury to it or staff 430 
then a schedule 1 method would be used. The captive bolt would be administered by a person 431 
licensed to use a captive bolt. One animal became ill and stopped eating during the 432 
experiment, the animal was monitored by the onsite vet, but started losing weight and 433 
exhibited a deteriorating condition. It was determined that the licence endpoint was likely to 434 
be reached and so to prevent this occurrence and any potential suffering by the animal, it was 435 
culled by the schedule 1 method of overdose of anaesthetic. Death was confirmed by 436 
cessation of blood flow. All other animals enjoyed excellent health for the duration of the 437 
experiment. At the end of the experiment all animals were culled using a schedule 1 method 438 
and death confirmed before necropsy. Food and water were supplied ad libitum.  439 
 440 
Recombinant proteins and R848 441 
HIV gp140, a trimeric gp140 clade C envelope (gp120 plus the external domain (ED) of 442 
gp41) and designated CN54gp140, was produced as a recombinant product in CHO cells and 443 
the protein manufactured to GMP specification by Polymun Scientific (Vienna, Austria). The 444 
identity of the product was confirmed by mass spectrometric analysis of tryptic fragments by 445 
the Medical Biomics Centre at St. George’s, University of London. The trimeric product was 446 
stable, and has been extensively tested to validate stability even when kept at room 447 
temperature (D. Katinger - personal communication) and has previously been reported to be 448 
immunogenic.  Water soluble resiquimond (R848), a low molecular weight imidazoquinoline 449 
compound was obtained from Axxora (NY, USA). MED-6382 silicone elastomer was 450 
obtained from Nusil Technology, USA. Tetrapropoxysilane (TPOS), stannous-2-451 
ethylhexanaote (catalyst), hydroxypropyl methyl cellulose (HPMC, 6cps), were obtained 452 
from Sigma Aldrich. 453 
 454 
Preparation of rings 455 
Human sized silicone elastomer vaginal rings, containing three cavities spaced equidistantly 456 
around the ring, were prepared by elevated temperature reaction injection moulding (T=80 457 
oC, 2 min) of MED-6382 silicone elastomer mix on a laboratory-scale ring-making machine 458 
fitted with specially-designed injection moulds (Fig. 9a+b). Briefly, silicone elastomer MED-459 
6382 was thoroughly mixed with 2.5% w/w TPOS using an overhead stirrer. 30 g of this 460 
mixture was mixed with 0.5% w/w of stannous-2-ethylhexanoate (catalyst) using a DAC 150 461 
FVZ-K Speedmixer™ (3000 rpm, 30 s) and injected into the moulds, mounted on a custom, 462 
laboratory scale, electrically-heated injection moulding machine. The dimensions of the ring 463 
were: outer diameter: 5.8 cm, inner diameter: 4.3 cm and cross-sectional diameter: 0.76 cm. 464 
 465 
Figure 9: A and B – Design of injection molds for fabrication of rod-insert vaginal ring 466 
devices. In B, the dashed boxes highlight the pins that create the cavities in the ring device. C 467 
– Examples of freeze-dried rod inserts prepared in PVC tubing. The upper rod insert is shown 468 
immediately after manufacture; the lower rod insert shows ingression of release medium. D – 469 
A silicone elastomer vaginal ring body into which three freeze-dried rod containing gp140 470 
have been inserted. 471 
Preparation of rod-inserts 472 
Resiqimod (27.7 mg), hydroxypropyl methyl cellulose (799.8 mg), gp140 solution (2700 μL), 473 
and sterile water (473 μL) were added sequentially to a 10 mL Speedmixer™ container and 474 
mixed (60 s, 3000 rpm). The gel mixture was hydrated overnight at 2-8 oC, followed by 475 
further mixing. The gel was injected into pre-cut sections of medical-grade PVC tubing 476 
(Nalgene® metric, 7.0 mm length, 2.0 mm internal diameter, 4.0 mm outer diameter) using a 477 
1 mL disposable plastic syringe fitted with a modified micropipette tip. Gel-filled tubes were 478 
placed on a stainless steel tray and freeze-dried (AdVantage freeze drier, VirTis, USA). The 479 
freeze drying involved ramping to -60 oC and holding for 2 h, followed by primary drying at -480 
30 oC for 15 h and finally ramping to +20 oC over 60 min and holding for 10 h [15]. After 481 
freeze-drying, the rods (figure 9c) were removed from the tubes and weighed. A single rod 482 
was inserted into each ring cavity (figure 9d). The rings were packaged in pre-labelled semi-483 
permeable paper-plastic ring pouches and heat-sealed using a PacSeal® impulse heat sealer. 484 
Each ring device carried a total of gp140 (500 μg) and R848 (500 μg). Similar rods not 485 
containing resiqimod were also prepared by omitting its addition during preparation. 486 
 487 
Release of CN54gp140 protein from silicone elastomer encapsulated rod 488 
Individual silicone elastomer rods containing CN54gp140 protein or CN54gp140 protein plus 489 
R848 were individually placed into 15mL polypropylene tubes with 2 mL PBS pH 7.2 or 2 490 
mL simulated vaginal fluid (SVF) pH4.2 [33]. Each rod contained 167 μg CN54gp140 and 491 
167 μg R848 with n=6 repeats for each rod formulation type and buffer, tubes were incubated 492 
in an orbital shaker at 37 °C, 100 rpm. The total 2 mL release media was removed with 493 
complete media replacement at the sampling timepoints 1, 3, 6, 12, 24, 48, 72, 96, 120, 144, 494 
168 h. CN54gp140 was quantified by a quantitative direct capture ELISA. Briefly, maxisorp 495 
high binding 96-well plates were coated overnight with 10 μg/mL sheep anti-gp120 HIV 496 
polyclonal antibody D7234 (Aalto Bio Reagents, Ireland), blocked with 1% BSA, 0.05% 497 
Tween-20, washed and then incubated with the sample before detection with the anti-gp41 498 
HIV human 5F3 antibody followed by anti-human IgG HRP and final development with 50 499 
µL/well of KPL SureBlue TMB substrate (Insight Biotechnology, UK) and stopped after 5 500 
min by adding 50 µL/well 1 M H2SO4, and the absorbance read at 450 nm on a VersaMax  501 
spectrophotometer using SoftmaxPro software. All incubations were for 1 h at 37 °C and 502 
plates washed between each step. 503 
 504 
Sheep, immunisation and sampling 505 
Female Welsh Beulah Speckled Face sheep were used in all experiments. All ewes had 506 
previously been used for breeding and were between 2 and 3 years of age. Sheep received an 507 
intramuscular injection of 100 µg HIV CN54gp140 + 200 µg R848 followed by three 508 
successive ring applications, each of one week duration and separated by one month intervals 509 
to allow development of somatically hypermutated antigen-reactive B cells in the draining 510 
lymph nodes. Each IM dose was administered in a total volume of 500 μL. Other sheep 511 
received only the ring devices without IM priming. The ring inserts contained a total of 500 512 
µg CN54gp140 recombinant protein per 3 rods, with some rods also containing 500 µg R848 513 
per 3 rods. 3 rods were inserted into each ring.  Rings were inserted into the vagina using a 514 
medium sized speculum to open the vaginal canal and were placed around the cervical 515 
opening. Serum and vaginal mucosal fluids were sampled every two weeks and analysed by 516 
CN54gp140 ELISA. Antigen-specific cellular responses were determined at necropsy. The 517 
studies utilizing the model antigen HIV Env CN54gp140 used five animals per group.  518 
Blood drawn from the leg vein was allowed to clot at room temperature for 30 min then 519 
centrifuged at 500 × g for 10 min and the serum removed and stored in aliquots at –80 0C. 520 
Vaginal sampling was performed by first inserting a medium-long sized speculum into the 521 
vagina to allow access to the vaginal wall and 2 x Weck-Cel® (Beaver-Visitec International, 522 
USA) cellulose sponge spears, pre-wet with 30 μL antibody extraction buffer (2 x PBS + 523 
Protease Inhibitor cocktail) were placed into the vagina and the speculum removed. The 524 
sponges were allowed to absorb fluid within the vagina for 5 min before removal by hand and 525 
the tips cut off while being placed into the top chamber of a Spin-X column. A further 300 μl 526 
of antibody extraction buffer was added into the top chamber of the Spin-X column with the 527 
two Weck-Cel® cellulose spears and allowed to incubate at RT for 10 min. The Spin-X® 528 
column was then centrifuged at 12,000 g for 15 min to remove large debris and isolate the 529 
fluid containing the high salt eluted antibody which was then frozen at –80 °C.  530 
 531 
Antigen-specific antibody semi-quantitative ELISA 532 
Serum and mucosal antigen-specific binding antibodies against HIV CN54gp140 533 
recombinant protein were measured using a standardized ELISA. Maxisorp® high binding 96-534 
well plates were coated with 50 µL recombinant proteins at 5 µg/mL in PBS overnight at 535 
4°C. The standard IgG or IgA immunoglobulins were coated onto the Maxisorp® plates 536 
overnight at 4°C.  Coated plates were washed three times in PBS-T before blocking with 200 537 
µL PBS-T containing 1% bovine serum albumin for 1 hr at 37 °C. After further washing, sera 538 
diluted 1/100, 1/1,000 and 1/10,000 or mucosal samples diluted 1/10, 1/50 and 1/250 were 539 
added to the antigen coated wells at 50 µL/well and incubated for 1 hr at 37°C. Plates were 540 
washed four times before the addition of 100 µL of a 1/500 dilution of rabbit anti-sheep IgG-541 
HRP or a 1/1,100 dilution of rabbit anti-sheep IgA secondary antibody and incubated for 1 542 
hour at 37°C. The plates were washed four times and developed with 50 µL/well of KPL 543 
SureBlue TMB substrate (Insight Biotechnology, UK). The IgA isotype, required a secondary 544 
antibody incubation step using goat anti-rabbit Ig biotin and a subsequent streptavidin-HRP 545 
(R&D systems) amplification step prior to TMB development. The reaction was stopped after 546 
5 min by adding 50 µL/well 1 M H2SO4, and the absorbance read at 450 nm on a 547 
VersaMax™ spectrophotometer using SoftmaxPro software.  548 
 549 
Flow Cytometry 550 
Cells were harvested from the animals at necropsy. External and internal iliac lymph nodes, 551 
the spleen and peripheral blood were harvested and lymphocytes isolated. Single cell 552 
suspensions of lymphocytes derived from each of these tissues were incubated with an aqua 553 
viability dye, washed 1x with 10 volumes PBS/0.5% FBS and then incubated with 1 ug/mL 554 
Alexa 647-conjugated CN54gp140 HIV Env protein or the control 1 μg/mL Alexa 647-555 
conjugated TT protein for 30 min at room temperature, washed 2x with 10 volumes 556 
PBS/0.5% FBS and then resuspended to a single cell suspension in 250 μL PBS before 557 
fixation with paraformaldehyde, final concentration of 1.5%. Dead cells were gated out using 558 
the live/dead cell aqua dye and the Alexa-647 positive staining assessed on live cells. 559 
Statistical Analysis 560 
The mean serum, mucosal antibody and antigen-specific flow binding data were compared 561 
using two-tailed Mann Whitney non-parametric tests or an unpaired t-test with Welch’s 562 
correction if the data variance was not equal. 563 
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695 
Figure Legends 696 
 697 
Figure 1: CN54gp140 in vitro release profile. Individual freeze-dried silicone elastomer 698 
rods were laced into 2 mL release media (PBS, pH 7.2 or SVF, pH 4.2). Rods contained 699 
CN54gp140 alone (167 µg) or CN54gp140 + R848 (167 µg each). The amount of 700 
CN54gp140 released into the 2 mL media was measured by quantitative ELISA and plotted 701 
as cumulative % release. Plot symbols represent the mean ± standard deviation of six 702 
replicates.  703 
 704 
Figure 2: Vaccination, bleed and vaginal sampling schedule. Two-year-old sheep were 705 
immunised at monthly intervals using intravaginal rings containing CN54gp140 HIV Env 706 
antigen +/- R848 adjuvant. The rings were maintained in place at the cervicovaginal area for 707 
1 week before removal. Some sheep received a prior IM vaccination one month before the 708 
insertion of the rings. Animals were bled weekly and had vaginal mucosal antibody Weck-709 
Cel® swabs taken at the times indicated. 710 
 711 
Figure 3: CN54gp140 antigen-specific antibody serum responses to 500 μg vaccine 712 
antigen in the presence of 500 μg R848 adjuvant per vaginal ring. IM Primed – animals 713 
received an IM prime at day 0 then three vaginal ring placements, each retained in situ for 7 714 
days, at monthly intervals. Unprimed – animals received the vaginal rings without a prior IM 715 
vaccination. The shaded areas indicate the 7-day periods during which a ring device was 716 
present in the sheep vagina. (A) Vaccine antigen-specific IgG and (B) IgA responses. Data 717 
compared with a Mann-Whitney test (n = 5 per group). 718 
 719 
 720 
Figure 4: CN54gp140 antigen-specific antibody mucosal responses to 500 μg vaccine 721 
antigen in the presence of 500 μg R848 adjuvant per vaginal ring. IM Primed – animals 722 
received an IM prime at day 0 then three vaginal ring placements, each retained in situ for 7 723 
days, at monthly intervals. Unprimed – animals received the vaginal rings without a prior IM 724 
vaccination. The shaded areas indicate the 7-day period during which a ring device was 725 
present in the sheep vagina. (A) Vaccine antigen-specific mucosal IgG and (B) mucosal IgA 726 
responses. Data compared with a Mann-Whitney test (n = 5 per group). 727 
 728 
Figure 5: CN54gp140 antigen-specific antibody serum responses to 500 μg vaccine 729 
antigen in the absence of R848 adjuvantation. IM primed – animals received an IM prime 730 
at day 0 then three vaginal ring placements, each retained in situ for 7 days, at monthly 731 
intervals. Unprimed – animals received the vaginal rings without a prior IM vaccination. The 732 
shaded areas indicate the 7-day periods when the vaginal ring was present. (A) Vaccine 733 
antigen-specific IgG and (B) IgA responses. Data compared with a Mann-Whitney test (n = 5 734 
per group). 735 
 736 
Figure 6: CN54gp140 antigen-specific serum antibody responses in animals that 737 
received only IM vaccinations. Animals received an IM prime of 100 μg vaccine antigen 738 
plus 200 μg R848 adjuvant at day 0 then three IM boost vaccinations with the same vaccine 739 
composition at monthly intervals. Vaccine antigen-specific IgG and IgA responses (n = 5 per 740 
group), 741 
 742 
Figure 7: CN54gp140 antigen-specific vaginal antibody responses in animals that 743 
received only IM vaccinations. Animals received an IM prime of 100 μg vaccine antigen 744 
plus 200 μg R848 adjuvant at day 0 then three IM boost vaccinations with the same vaccine 745 
composition at monthly intervals. Vaccine antigen-specific mucosal IgG and mucosal IgA 746 
responses (n = 5 per group). 747 
 748 
Figure 8: Elicitation of Antigen-Specific B cells in vaginal local draining lymph nodes. 749 
Cells were harvested from the peripheral blood, the spleen or the vaginal external iliac lymph 750 
nodes and stained with Alexa-647 conjugated recombinant CN54gp140 protein. 751 
 752 
Figure 9: A and B – Design of injection molds for fabrication of rod-insert vaginal ring 753 
devices. In B, the dashed boxes highlight the pins that create the cavities in the ring device. C 754 
– Examples of freeze-dried rod inserts prepared in PVC tubing. The upper rod insert is shown 755 
immediately after manufacture; the lower rod insert shows ingression of release medium. D – 756 
A silicone elastomer vaginal ring body into which three freeze-dried rod containing gp140 757 
have been inserted. 758 
 759 
 760 
761 
Tables 762 
Table 1: Sheep groups and immunization schedule (n = 5). IM – intramuscular 763 
administration of 100 µg CN54gp140 + 200 µg R848; IVag – intravaginal administration of 764 
500 µg CN54gp140 ± 500 µg R848. 765 
 766 
Table 2: Serum and mucosal IgG and IgA levels (μg/mL) 2 weeks after each vaginal ring 767 
insertion (Days 42, 70 and 98) and at end of vaccination schedule (Day 112). (+/- SD in 768 
parentheses). IM – intramuscular administration of 100 µg CN54gp140 + 200 µg R848; IVag 769 
– intravaginal administration of 500 µg CN54gp140 ± 500 µg R848. A dash within a cell 770 
indicates that antibody levels were not detected. 771 
 772 
Table 3: Mean percentage of background control subtracted antigen-specific cells in each 773 
tissue (n=5 per group) (+/- SD in parentheses). 774 
 775 
Supplementary Material  776 
Supplementary Figure 1: Elicitation of Antigen-Specific B cells in vaginal local draining 777 
lymph nodes of animals that received intravaginal rings containing CN54gp140 only. 778 
Cells were harvested from the peripheral blood, the spleen or the vaginal external iliac lymph 779 
nodes and stained with Alexa-647 conjugated recombinant CN54gp140 protein. 780 
 781 
 782 
 783 
Supplementary Figure 2: Excised sheep vagina at necropsy. A vaginal ring antigen-784 
release device in situ within a vagina removed from a culled sheep. No inflammation or 785 
infection is apparent on the vaginal vault wall. Note that the lyophilized rod that originally 786 
contained the vaccine formulation is no longer present in the visible ring cavity. 787 
 788 
